Stroke-related epilepsy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Stroke is the cause of about 10% of all epilepsy and 55% of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke-related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25% of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide high-quality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre-clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.

Original languageEnglish (US)
JournalEuropean Journal of Neurology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Epilepsy
Stroke
Seizures
Anticonvulsants
Primary Prevention
Secondary Prevention
Hospitalization
Therapeutics
Morbidity
Brain
Pharmaceutical Preparations

Keywords

  • epilepsy
  • epileptogenesis
  • focal epilepsy
  • post-stroke epilepsy
  • stroke
  • symptomatic epilepsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Stroke-related epilepsy. / Feyissa, Anteneh; Hasan, T. F.; Meschia, James F.

In: European Journal of Neurology, 01.01.2018.

Research output: Contribution to journalArticle

@article{4776ce7c184d4d2aa0993c274943650c,
title = "Stroke-related epilepsy",
abstract = "Stroke is the cause of about 10{\%} of all epilepsy and 55{\%} of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke-related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25{\%} of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide high-quality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre-clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.",
keywords = "epilepsy, epileptogenesis, focal epilepsy, post-stroke epilepsy, stroke, symptomatic epilepsy",
author = "Anteneh Feyissa and Hasan, {T. F.} and Meschia, {James F}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ene.13813",
language = "English (US)",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Stroke-related epilepsy

AU - Feyissa, Anteneh

AU - Hasan, T. F.

AU - Meschia, James F

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Stroke is the cause of about 10% of all epilepsy and 55% of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke-related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25% of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide high-quality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre-clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.

AB - Stroke is the cause of about 10% of all epilepsy and 55% of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke-related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25% of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide high-quality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre-clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.

KW - epilepsy

KW - epileptogenesis

KW - focal epilepsy

KW - post-stroke epilepsy

KW - stroke

KW - symptomatic epilepsy

UR - http://www.scopus.com/inward/record.url?scp=85055058981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055058981&partnerID=8YFLogxK

U2 - 10.1111/ene.13813

DO - 10.1111/ene.13813

M3 - Article

C2 - 30320425

AN - SCOPUS:85055058981

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

ER -